Insider · SEC Form 4 filer
Kevin Freeman
Past buys: 2 of 4 beat
Companies
Where they file as an insider
Galectin Therapeutics (GALT) Director Latest filing Dec 23, 2025
Track record
Did their buys beat the typical stock?
Open-market buys8
Quarters checked 6 months later4
Beat the typical stock 2 of 4
Quarters too new to check0
2 of 4 checked quarters beat the typical stock. A past record is data, not a forecast.
Galectin Therapeutics (GALT) Bought Dec 23, 2025 · $19.5K · 5,500 shares Beat typical Dec 31, 2025 $4.16 → Jun 30, 2026 $4.64 · +11.5% (typical stock +4.7%)
Galectin Therapeutics (GALT) Bought Jul 17, 2025 · $14.5K · 5,000 shares Behind typical Sep 30, 2025 $4.24 → Mar 31, 2026 $2.79 · −34.1% (typical stock −3.4%)
Galectin Therapeutics (GALT) Bought Oct 16–Dec 24, 2024 · $38.5K · 21,300 shares Beat typical Dec 31, 2024 $1.29 → Jun 30, 2025 $2.11 · +63.6% (typical stock −3.4%)
Galectin Therapeutics (GALT) Bought Apr 22–Jun 20, 2024 · $13.4K · 5,000 shares Behind typical Jun 30, 2024 $2.26 → Dec 31, 2024 $1.29 · −42.9% (typical stock +3.9%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.